Page 1

Global Markets for Generic Drugs

Summary The global market for generic drugs should reach $533 billion by 2021 from $352 billi on in 2016 at a compound annual growth rate (CAGR) of 8.7%, from 2016 to 2021. INTRODUCTION STUDY GOALS AND OBJECTIVES The aim of this report is to provide detailed market, technology & industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified & sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics and other factors that directly affect the generic drug market. The wider economic environment is also taken into account. The report examines strategies employed by companies specializing in generics to mee t the challenges of this highly competitive market, while also summarizing strategies employed by “originator� companies to respond to generic competition.

REASONS FOR DOING THE STUDY This is a time of growth & change for the generic pharmaceutical sector. Major aspects that have combi ned to create an opportunity for an up-to date market analysis include the following: -The demand for generic is increasing steadily because of pressure to control healthcare costs. At the sa me time, fierce price competition in this area has put some companies in difficulties because of slashed profit margins. The main result has been a wave of M&A activity, and the rise of “supergenerics” offeri ng added value as well as low prices. Not all traditional companies are positioned to exploit this trend. -A major growth driver for the generics sector is the fact that several blockbuster pharmaceutical brands are coming off-patent and are therefore open to generic competition – the phenomenon widely known as the “patent cliff.” But the originator companies are deploying formidable strategies to protect their franchise, including marketing their own branded generics. -With first-generation biopharmaceutical products reaching the end of their patent lives, a whole new m arket field — biogenerics, or biosimilars — is opening up, for those generics companies capable of (or prepared to buy in) the technological expertise required. -The international landscape is changing for generics as for all pharmaceuticals. The BRIC nations (Brazil, Russia, India and China) are among rising centers of generic activity.

SCOPE OF REPORT This report discusses the implications of all the above-mentioned trends, in the context of the current size and growth of the generics market, both in global terms and analyze d by the most important national markets. The nature & structure of the generics indust ry is discussed, with profiles of the leading 20+ generics companies & an update on M &A activity. Five-year sales forecasts are provided for the national markets and the maj or therapeutic categories of products involved.

MARKET ANALYSES & FORECASTS Market figures are based on revenues at the manufacturer level and are projected on the basis of 2016 dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories quantified and forecast include antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g. hypolipidemics and antihypertensive) and drugs for respiratory conditions, including asthma and COPD.

METHODOLOGY Primary research includes interviews with leading individuals in generics companies, industry associations and regulatory bodies. Primary sources of published data include company annual reports, SEC filings, and government and industry publications. Secondary sources consist of literature searches, industry journals & other commercial publications. Data for market estimates & forecasts are pooled from a range of sources, critically assessed by Research team.

INTENDED AUDIENCE This report is designed to satisfy the information needs of a wide variety of individuals involved in the generics marketplace, including corporate senior management executiv e seeking to base their strategic decisions on the best available information on market forces and trends. It is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date back ground on the marketplace in which they are operating.

INFORMATION SOURCES Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles & data from healthcare institutions wer e also mined, as well as publications of trade associations such as the Generic Pharmaceutical Association (GPhA) and the European Generic Medicines Association (EGA).

Table of Contents  Introduction  Summary  Overview  The New Generics Era  Major Generic Issues  The Generics Market  Generics Markets And Forecasts By Country  The Global Generics Industry

Full Reports

Global Markets for Generic Drugs

Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Email: Website: FaceBook : BharatBook3B Twitter : ResearchBook LinkedIn : Bharat Book Bureau

Thank You

Global markets for generic drugs  

Bharat Book presents the report on “Global Markets for Generic Drugs” (

Read more
Read more
Similar to
Popular now
Just for you